Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor

- Claus Andersson, PhD, joins Rewinds Board of Directors

Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.

Claus Andersson, PhD, General Partner at Sunstone Life Science Ventures A/S, will join Rewind Therapeutics Board of Directors. Financial details of the transaction were not disclosed.

The proceeds will be used to advance Rewind Therapeutics lead program into clinical development and further broaden the Companys pipeline of drug candidates designed to restore the remyelination function of the central nervous system (CNS). Myelin forms a protective layer around neurons and is essential for their proper functioning. Neurodegenerative disorders such as multiple sclerosis are associated with a damaged, deteriorating myelin sheath, which ultimately leads to a range of symptoms such as depression, anxiety, irritability, and even death due to a breakdown of the vital neurological functions.